Effectiveness and Safety of use ior LeukoCIM as prophylaxis and treatment of Neutropenia in patients with HIV / AIDS.
Phase 4
Completed
- Conditions
- eutropenia in patients with HIV/AIDS.
- Registration Number
- RPCEC00000085
- Lead Sponsor
- Center of Molecular Inmunology(CIM)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1.HIV/AIDS patients who are or not associated to an opportunistic malignant disease and who meet the diagnostic criteria. 2.Patients who signed their consent in order to participate in the study. 3.Patients older than 18 years. 4.Patients of both sexes.
Exclusion Criteria
1.Patients with known hypersensitivity to E.Coli cell products or other preparations of rG-CSF. 2.Pregnant patients or breastfeeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recovery of Absolute Neutrophil count (ANC) numbers = 1.5 x109/L (Yes/No), Measurement time: 5-8 days.
- Secondary Outcome Measures
Name Time Method